(PharmaNewsWire.Com, February 21, 2019 ) A new report by Fact.MR projects the global market for peptide and heparin to reflect an impressive expansion during the forecast period, 2017 to 2026. Revenues from the market are estimated to exceed US$ 34,000 Mn by 2026-end.
Peptides are amino acids’ short chains connected through peptide bonds. Peptides are molecules that are commonly known as proteins, whose functions are determined on the basis of the amino acid sequence and size. Heparin is known as disaccharide anticoagulant, commonly referred to as blood thinner, which prevents formation of blood clots. Mast cells and basophils in a body produce heparin, which is stored in mast cells and secreted wherever injuries occur.
The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors. These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas. Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future. Key market participants identified by the report include Baxter, Celsus, Biofer S.p.A,, Hemmo Pharma, AmbioPharm, Inc., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., Bachem, Abbott Laboratories, Pfizer Inc., Aspen, Leo Pharma, Teva, Takeda, Sanofi, Novo Nordisk, and Eli Lilly.
Drug Developers Shifting Back to Peptides owing to Mounting Challenges regarding Small Molecules
While the pharmaceutical sector discerned small molecules as the medicinal agents, therapeutic peptides were considered to be niche products. However, with mounting challenges regarding small molecules, drug developers are shifting their concentration back to small amino acid chains. Although peptides have been deemed ineffective for developing drugs, modern peptide drug designs and formulations have been developed for circumventing their weaknesses. For example, original requirement for injecting peptides such as insulin is fading, with more patient-friendly administrations progressively being developed. In addition, the current society that critically judges undesirable effects and environmental impact of the candidate medicines is embracing the safety offered by peptides.
Heparin is being extensively employed as an antitumor and anti-inflammatory agent. The anti-inflammatory characteristic of heparin, which prevents metastatic spreading of tumor cells, is a new research finding among healthcare professionals. The metastatic spreading of tumor cells is restricted by heparin through neutralization of cationic mediators, inhibition of heparanase, and adhesion molecules. Recent discoveries have meant that heparin is capable of targeting L- and P-selectin & integrin activity, as well as preventing cancer progression.
APEJ to Remain Most Remunerative Market for Peptide and Heparin
There has been a growing demand for new oral anticoagulants having better efficacy and safety profiles in Asia-Pacific excluding Japan (APEJ). Side effects related to heparin products, including complications of bleeding and heparin-induced thrombocytopenia has resulted into robust adoption of oral anticoagulants in the region. In addition, rising incidence of cancer, metabolic disorders, and hepatitis, along with advancements in peptide synthesis technology and rapid demand for various peptide therapies in the region are expected to drive the growth in APEJ. APEJ will remain the most remunerative market for peptide and heparin.
Liraglutide and ammonium heparin are expected to remain fast-expanding products in the market. In addition, sales of exenatide, lithium heparin, and sodium heparin will register a similar CAGR through 2026.
Key Research Findings from Fact.MR’s Report on Peptide and Heparin Market
Oral route of administration will remain preferred for peptide and heparin Cancer will continue to be the dominant indication segment in the market, in terms of revenues Hospital pharmacies will remain the most lucrative distribution channel for peptide and heparin Speak To Research Analyst for Detailed Insights @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=378
Table of Contents Covered in the report are:
1. Global Economic Outlook
2. Global Peptide and Heparin Market - Executive Summary
3. Global Peptide and Heparin Market Overview 3.1. Introduction 3.1.1. Global Peptide and Heparin Market Taxonomy 3.1.2. Global Peptide and Heparin Market Definition 3.2. Global Peptide and Heparin Market Size (US$ Mn) and Forecast, 2012-2026 3.2.1. Global Peptide and Heparin Market Y-o-Y Growth 3.3. Global Peptide and Heparin Market Dynamics 3.4. Supply Chain 3.5. Cost Structure 3.6. PESTLE Analysis 3.7. Product Lifecycle 3.8. List of Distributors 3.9. Key Participants Market Presence (Intensity Map) By Region
4. Global Peptide and Heparin Market Analysis and Forecast 2012-2026 4.1. Global Peptide and Heparin Market Size and Forecast By Product Type , 2012-2026 4.1.1. Sodium Heparin Market Size and Forecast, 2012-2026 4.1.1.1. Revenue (US$ Mn) Comparison, By Region 4.1.1.2. Market Share Comparison, By Region 4.1.1.3. Y-o-Y growth Comparison, By Region 4.1.2. Ammonium Heparin Market Size and Forecast, 2012-2026 4.1.2.1. Revenue (US$ Mn) Comparison, By Region 4.1.2.2. Market Share Comparison, By Region 4.1.2.3. Y-o-Y growth Comparison, By Region 4.1.3. lithium Heparin Market Size and Forecast, 2012-2026 4.1.3.1. Revenue (US$ Mn) Comparison, By Region 4.1.3.2. Market Share Comparison, By Region 4.1.3.3. Y-o-Y growth Comparison, By Region 4.1.4. Icatibant Market Size and Forecast, 2012-2026 4.1.4.1. Revenue (US$ Mn) Comparison, By Region 4.1.4.2. Market Share Comparison, By Region 4.1.4.3. Y-o-Y growth Comparison, By Region 4.1.5. Bivalirudin Market Size and Forecast, 2012-2026 4.1.5.1. Revenue (US$ Mn) Comparison, By Region 4.1.5.2. Market Share Comparison, By Region 4.1.5.3. Y-o-Y growth Comparison, By Region 4.1.6. Liraglutide Market Size and Forecast, 2012-2026 4.1.6.1. Revenue (US$ Mn) Comparison, By Region 4.1.6.2. Market Share Comparison, By Region 4.1.6.3. Y-o-Y growth Comparison, By Region 4.1.7. Exenatide Market Size and Forecast, 2012-2026 4.1.7.1. Revenue (US$ Mn) Comparison, By Region 4.1.7.2. Market Share Comparison, By Region 4.1.7.3. Y-o-Y growth Comparison, By Region 4.1.8. Goserelin Market Size and Forecast, 2012-2026 4.1.8.1. Revenue (US$ Mn) Comparison, By Region 4.1.8.2. Market Share Comparison, By Region 4.1.8.3. Y-o-Y growth Comparison, By Region 4.1.9. Bortezomib Market Size and Forecast, 2012-2026 4.1.9.1. Revenue (US$ Mn) Comparison, By Region 4.1.9.2. Market Share Comparison, By Region 4.1.9.3. Y-o-Y growth Comparison, By Region 4.1.10. Other Product Types Market Size and Forecast, 2012-2026 4.1.10.1. Revenue (US$ Mn) Comparison, By Region 4.1.10.2. Market Share Comparison, By Region 4.1.10.3. Y-o-Y growth Comparison, By Region 4.2. Global Peptide and Heparin Market Size and Forecast By Route of Administration , 2012-2026 4.2.1. Intravenous Market Size and Forecast, 2012-2026 4.2.1.1. Revenue (US$ Mn) Comparison, By Region 4.2.1.2. Market Share Comparison, By Region 4.2.1.3. Y-o-Y growth Comparison, By Region 4.2.2. Oral Route Market Size and Forecast, 2012-2026 4.2.2.1. Revenue (US$ Mn) Comparison, By Region 4.2.2.2. Market Share Comparison, By Region 4.2.2.3. Y-o-Y growth Comparison, By Region 4.2.3. Others Market Size and Forecast, 2012-2026 4.2.3.1. Revenue (US$ Mn) Comparison, By Region 4.2.3.2. Market Share Comparison, By Region 4.2.3.3. Y-o-Y growth Comparison, By Region 4.3. Global Peptide and Heparin Market Size and Forecast By Indication, 2012-2026 4.3.1. Diabetes Market Size and Forecast, 2012-2026 4.3.1.1. Revenue (US$ Mn) Comparison, By Region 4.3.1.2. Market Share Comparison, By Region 4.3.1.3. Y-o-Y growth Comparison, By Region 4.3.2. Cardiovascular Market Size and Forecast, 2012-2026 4.3.2.1. Revenue (US$ Mn) Comparison, By Region 4.3.2.2. Market Share Comparison, By Region 4.3.2.3. Y-o-Y growth Comparison, By Region 4.3.3. Cancer Market Size and Forecast, 2012-2026 4.3.3.1. Revenue (US$ Mn) Comparison, By Region 4.3.3.2. Market Share Comparison, By Region 4.3.3.3. Y-o-Y growth Comparison, By Region 4.3.4. Metabolic Disorder Market Size and Forecast, 2012-2026 4.3.4.1. Revenue (US$ Mn) Comparison, By Region 4.3.4.2. Market Share Comparison, By Region 4.3.4.3. Y-o-Y growth Comparison, By Region 4.3.5. Central Nervous Systems Market Size and Forecast, 2012-2026 4.3.5.1. Revenue (US$ Mn) Comparison, By Region 4.3.5.2. Market Share Comparison, By Region 4.3.5.3. Y-o-Y growth Comparison, By Region 4.3.6. Other Indications Market Size and Forecast, 2012-2026 4.3.6.1. Revenue (US$ Mn) Comparison, By Region 4.3.6.2. Market Share Comparison, By Region 4.3.6.3. Y-o-Y growth Comparison, By Region 4.4. Global Peptide and Heparin Market Size and Forecast By Distribution Channel, 2012-2026 4.4.1. Hospital Pharmacies Market Size and Forecast, 2012-2026 4.4.1.1. Revenue (US$ Mn) Comparison, By Region 4.4.1.2. Market Share Comparison, By Region 4.4.1.3. Y-o-Y growth Comparison, By Region 4.4.2. Retail Pharmacies Market Size and Forecast, 2012-2026 4.4.2.1. Revenue (US$ Mn) Comparison, By Region 4.4.2.2. Market Share Comparison, By Region 4.4.2.3. Y-o-Y growth Comparison, By Region 4.4.3. Market Size and Forecast, 2012-2026 4.4.3.1. Revenue (US$ Mn) Comparison, By Region 4.4.3.2. Market Share Comparison, By Region 4.4.3.3. Y-o-Y growth Comparison, By Region
5. North America Peptide and Heparin Market Size and Forecast, 2012-2026 5.1. North America Outlook 5.2. North America Parent Market Outlook 5.3. North America Target Market Outlook 5.4. Revenue (US$ Mn) Comparison, By Country 5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026 5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026 5.5. Revenue (US$ Mn) Comparison, By Product Type 5.6. Revenue (US$ Mn) Comparison, By Route of Administration 5.7. Revenue (US$ Mn) Comparison, By Indication 5.8. Revenue (US$ Mn) Comparison, By Distribution Channel
6. Latin America Peptide and Heparin Market Size and Forecast, 2012-2026 6.1. Latin America Outlook 6.2. Latin America Parent Market Outlook 6.3. Latin America Target Market Outlook 6.4. Revenue (US$ Mn) Comparison, By Country 6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026 6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026 6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026 6.5. Revenue (US$ Mn) Comparison, By Product Type 6.6. Revenue (US$ Mn) Comparison, By Route of Administration 6.7. Revenue (US$ Mn) Comparison, By Indication 6.8. Revenue (US$ Mn) Comparison, By Distribution Channel
And Continue...
Table and Figures Covered in the report are:
TABLE 1 Global Peptide and Heparin Market Value (US$ Mn), 2012-2017 TABLE 2 Global Peptide and Heparin Market Value (US$ Mn), 2018-2026 TABLE 3 Global Peptide and Heparin Market Value (US$ Mn) and Y-o-Y, 2017-2026 TABLE 4 Global Sodium Heparin Segment Value (US$ Mn), By Region 2012-2017 TABLE 5 Global Sodium Heparin Segment Value (US$ Mn), By Region 2018-2026 TABLE 6 Global Sodium Heparin Segment Market Share, By Region 2012-2017 TABLE 7 Global Sodium Heparin Segment Market Share, By Region 2018-2026 TABLE 8 Global Sodium Heparin Segment Y-o-Y, By Region 2017-2026 TABLE 9 Global Ammonium Heparin Segment Value (US$ Mn), By Region 2012-2017 TABLE 10 Global Ammonium Heparin Segment Value (US$ Mn), By Region 2018-2026
And Continue...
FIG. 1 Global Peptide and Heparin Market Value (US$ Mn), 2012-2017 FIG. 2 Global Peptide and Heparin Market Value (US$ Mn) Forecast, 2018-2026 FIG. 3 Global Peptide and Heparin Market Value (US$ Mn) and Y-o-Y, 2017-2026 FIG. 4 Global Sodium Heparin Segment Market Value (US$ Mn) By Region, 2012-2017 FIG. 5 Global Sodium Heparin Segment Market Value (US$ Mn) By Region, 2018-2026 FIG. 6 Global Sodium Heparin Segment Y-o-Y Growth Rate, By Region, 2017-2026 FIG. 7 Global Ammonium Heparin Segment Market Value (US$ Mn) By Region, 2012-2017 FIG. 8 Global Ammonium Heparin Segment Market Value (US$ Mn) By Region, 2018-2026 FIG. 9 Global Ammonium Heparin Segment Y-o-Y Growth Rate, By Region, 2017-2026 FIG. 10 Global lithium Heparin Segment Market Value (US$ Mn) By Region, 2012-2017
And Continue...
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us Rohit Bhisey Fact.MR 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Email: sales@factmr.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
